ClinicalTrials.gg
Active, not recruitingNCT05364073Updated Nov 12, 2026

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

A Phase 1 interventional study of Furmonertinib and Furmonertinib in Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer and Advanced Non-Small Cell Lung Cancer, sponsored by ArriVent BioPharma, Inc.. Active, not recruiting at 42 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by ArriVent BioPharma, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
160
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung — 31 open to participants now, 34 under way, 5 of them phase 3. aflutinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
10th of 41
160 · median 60
Started
2022
with 6 others
Phase 1
4 of 41
1 open now
Primary completion
2025-06
later than 6 of 33 live
Registered
9th of 41
by date
Lead sponsor
3 of 41
ArriVent BioPharma, Inc.

Among the 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung, this one is the 10th largest by enrollment, is one of 7 that started in 2022, is one of 4 in phase 1, reaches primary completion later than 6 of the 33 other live ones, and was the 9th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

31 of the 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About aflutinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase 1b, open-label, multi-center, dose-escalation and dose expansion study designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of furmonertinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating, including uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) mutations. Patients will be enrolled into one of 2 stages: Stage 1 (Dose Escalation and Backfill Cohorts) and Stage 2 (Dose Expansion).

03

Conditions studied

  • Non-Small Cell Lung Cancer (NSCLC)
  • Metastatic Non-Small Cell Lung Cancer
  • Advanced Non-Small Cell Lung Cancer
  • HER2 Exon 20 Mutations
  • EGFR Exon 20 Mutations
  • EGFR Uncommon Mutations, Including G719X and S768I

Keywords

  • Non-small cell lung cancer (NSCLC)
  • Metastatic Non-Small Cell Lung Cancer
  • Advanced Non-Small Cell Lung Cancer
  • EGFR
  • HER2
  • Exon 20 Insertion Mutations
  • HER2 kinase domain mutations
  • Epidermal Growth Factor Receptor (EGFR) kinase domain mutations
  • Exon 20
  • Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations
  • HER2 Exon 20 Insertion Mutations
  • Tyrosine Kinase Inhibitor (TKI)
  • Human Epidermal Growth Factor Receptor 2 (HER2)
  • Epidermal Growth Factor Receptor (EGFR)
  • EGFR uncommon mutations
  • EGFR atypical mutations
  • EGFR rare mutations
  • V774M
  • G719X
  • S768I
  • E709X
  • R776C/H
  • G724S
  • E736K
  • I740_K745dup
  • N771G
  • K757M/R
  • V769L/M
  • T854X
  • T751_I759delinsN
  • G719A
  • G719S
  • R776C
  • R776H
  • K757M
  • K757R
  • V769L
  • V769M
  • osimertinib
  • afatinib
  • E709_T710del insD
  • G779F
  • L747X
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • or cytologically documented, locally advanced or Non-Small Cell Lung Cancer (NSCLC) not amenable to curative surgery or radiotherapy.
  • Disease that has progressed after at least one available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable; or for whom a clinical trial of an agent is a recognized standard of care.
  • Documented radiologic disease progression during or after the last systemic anti-cancer therapy before the first dose of furmonertinib.
  • For patients with Epidermal Growth Factor Receptor (EGFR) mutations sensitive to osimertinib, the patient must have received osimertinib prior to study enrollment in regions where osimertinib is approved, including the US.

Stage 1 dose escalation and backfill cohorts and Stage 2 Cohorts 1, 2, 3 and 4:

-Patients with (including ) may be eligible if meeting additional protocol specified criteria.

Stage 1 Dose Escalation and Backfill Cohorts Inclusion Criteria:

- Documented validated results from local testing of tumor tissue or blood confirming the presence of an activating, including uncommon, EGFR mutation or exon 20 insertion mutation performed at a CLIA-or equivalently certified laboratory.

Stage 2 Cohort 1 Previously Treated, Locally Advanced or Metastatic NSCLC Patients with EGFR Exon 20 Insertion Mutations Inclusion Criteria

  • Documented validated results from local testing of either tumor tissue or blood confirming the presence of EGFR Exon 20 insertion mutations, performed at a CLIA- or equivalently certified laboratory.
  • The patient must have experienced disease progression or have intolerance to treatment with platinum-based chemotherapy.

Stage 2 Cohort 2 Previously treated, Locally Advanced or Metastatic NSCLC Patients with HER2 Exon 20 Insertion Mutations Inclusion Criteria

  • Documented validated results from local testing of either tumor tissue or blood confirming the presence of HER2 Exon 20 insertion mutations, performed at a CLIA- or equivalently certified laboratory.
  • The patient must have experienced disease progression or have intolerance to treatment with platinum-based chemotherapy.
  • In regions in which fam-trastuzumab deruxtecan-nxki is approved and available for adult patients with unresectable or metastatic NSCLC whose tumors have activating HER2 exon 20 mutations, the patient must have received or be considered not appropriate to receive fam-trastuzumab deruxtecan-nxki.

Stage 2 Cohort 3 Previously Treated, Locally Advanced or Metastatic NSCLC Patients with EGFR Activating Mutations Mutations, who are not eligible for Cohorts 1 and 4 Inclusion Criteria

  • Documented validated results from local testing of either tumor tissue or blood confirming the presence of an EGFR activating mutation, performed at a CLIA- or equivalently certified laboratory.
  • The patient must have experienced disease progression or have intolerance to treatment with the standard of care EGFR TKI.
  • Patients with CNS metastases may be eligible if meeting additional protocol specified criteria.

Stage 2 Cohort 4 Untreated or Previously Treated EGFR TKI-Naïve, Locally Advanced or Metastatic NSCLC Patients with EGFR Uncommon Mutations excluding EGFR Exon 20 insertions Inclusion Criteria

  • Previously untreated in the locally advanced or metastatic setting or have progressed after at least 1 available standard therapy, or for whom standard therapy has proven to be ineffective, intolerable, or considered inappropriate
  • Documented validated results from local testing of either tumor tissue or blood confirming the presence of an EGFR Uncommon mutation, performed at a CLIA- or equivalently certified laboratory a. Representative mutations include, but are not limited to, G719X, S768I, E709X, G779F, L747X, V774M, E709_T710delinsD, R776C/H, G724S, E736K, I740_K745dup, N771G, K757M/R, V769L/M, T854X, T751_I759delinsN

Key Exclusion Criteria:

  • Treatment with chemotherapy, targeted therapy, biologic therapy or an investigational agent as anti-cancer therapy within 3 or 3 elimination weeks or five half-lives prior to initiation of furmonertinib, whichever is shorter, or endocrine therapy within 2 weeks prior to initiation of furmonertinib.
  • Radiation therapy as cancer therapy within 4 weeks prior to initiation of furmonertinib.
  • Palliative radiation to bone metastases within 2 weeks prior to initiation of furmonertinib.
  • AE from prior anticancer therapy that have not resolved to Grade ≤ 1 except for alopecia or Grade ≤ 2 peripheral neuropathy.

Stage 2 Cohort 4 Untreated or Previously Treated EGFR TKI-Naïve, Locally Advanced or Metastatic NSCLC Patients with EGFR Uncommon Mutations Exclusion Criteria

  • Prior treatment with any EGFR TKIs
  • Progression during or adjuvant therapy (e.g., chemotherapy, radiotherapy, immunotherapy or investigational agents) or within 12 months of completion of above therapies.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Stage 1 Dose Escalation and Backfill

    Experimental: Previously treated patients with advanced or metastatic NSCLC with activating EGFR or HER2 mutations

    Drug: Furmonertinib

  • Experimental
    Stage 2 Expansion Cohort 1

    Previously Treated NSCLC Patients with EGFR Exon 20 Insertion Mutations

    Drug: Furmonertinib

  • Experimental
    Stage 2 Expansion Cohort 2

    Previously treated NSCLC Patients with HER2 Exon 20 Insertion Mutations

    Drug: Furmonertinib

  • Experimental
    Stage 2 Expansion Cohort 3

    Previously treated NSCLC Patients with EGFR Activating Mutations, who are not eligible for Cohorts 1 and 4

    Drug: Furmonertinib

  • Experimental
    Stage 2 Expansion Cohort 4

    Untreated or Previously treated EGFR TKI Naïve NSCLC Patients with EGFR Uncommon Mutations, excluding EGFR exon 20 insertion mutations

    Drug: Furmonertinib

Interventions

06

What researchers measure

Primary outcomes

  1. Stage 1: Number of incidence and severity of adverse events (AEs) as a measure of safety and tolerability of Furmonertinib

    Time frame: Up to 36 months after first dose

  2. Stage 2: Overall Response Rate (ORR)

    Time frame: Up to 36 months after first dose

Secondary outcomes

  1. Stage 1: Overall Response Rate

    Time frame: Up to 36 months after first dose

  2. Stage 1: Duration of Response (DOR)

    Time frame: Up to 36 months after first dose

  3. Stage 1: Disease Control Rate

    Time frame: Up to 36 months after first dose

  4. Stage 1: Progression Free Survival

    Time frame: Up to 36 months after first dose

  5. Stage 1: Depth of Response

    Time frame: Up to 36 months after first dose

  6. Stage 1: Overall survival

    Time frame: Up to 36 months after first dose

  7. Stage 1: Central Nervous System ORR

    Time frame: Up to 36 months after first dose

  8. Stage 1: Central Nervous System DOR

    Time frame: Up to 36 months after first dose

  9. Stage 1: Plasma concentrations of furmonertinib and its major metabolite (AST5902)

    Time frame: Up to 36 months after first dose

  10. Stage 1, Cohort 1, Backfill only: Plasma concentrations of furmonertinib and its major metabolite (AST5902)

    Time frame: Up to 36 months after first dose

  11. Stage 1, Cohort 1, Backfill only: Plasma concentrations of midazolam and its metabolite (1-OH-midazolam)

    Time frame: Up to 36 months after first dose

  12. Stage 2, all cohorts: Duration of Response

    Time frame: Up to 36 months after first dose

  13. Stage 2, all cohorts: Disease Control Rate

    Time frame: Up to 36 months after first dose

  14. Stage 2, all cohorts: Progression Free Survival

    Time frame: Up to 36 months after first dose

  15. Stage 2, all cohorts: Depth of Response

    Time frame: Up to 36 months after first dose

  16. Stage 2, all cohorts: Overall survival

    Time frame: Up to 36 months after first dose

  17. Stage 2, all cohorts: Central Nervous System ORR

    Time frame: Up to 36 months after first dose

  18. Stage 2, all cohorts: Central Nervous System DOR

    Time frame: Up to 36 months after first dose

  19. Stage 2, Cohort 4 only: Overall Response Rate

    Time frame: Up to 36 months after first dose

  20. Stage 2, all cohorts: Number of incidence and severity of AEs as a measure of safety and tolerability of Furmonertinib

    Time frame: Up to 36 months after first dose

  21. Stage 2, all cohorts: Plasma concentrations of furmonertinib and its major metabolite (AST5902)

    Time frame: Up to 36 months after first dose

07

Study locations

42 sites
  • ArriVent Investigative Site
    Prescott, Arizona 86301, United States
  • ArriVent Investigative Site
    Sacramento, California 95817, United States
  • ArriVent Investigative Site
    Whittier, California 90603, United States
  • ArriVent Investigative Site
    Celebration, Florida 34747, United States
  • ArriVent Investigative Site
    Detroit, Michigan 48202, United States
  • ArriVent Investigative Site
    Houston, Texas 77030, United States
  • ArriVent Investigative Site
    Fairfax, Virginia 22031, United States
  • ArriVent Investigative Site
    Blacktown, New South Wales 2148, Australia
  • ArriVent Investigative Site
    St Leonards, New South Wales 2065, Australia
  • ArriVent Investigative Site
    Heidelberg, Victoria 3084, Australia
  • Arrivent Investigative Site
    Edmonton, T6G 1Z2, Canada
  • Arrivent Investigative Site
    Toronto, M5G 2M9, Canada
  • Allist Investigative Site
    Hefei, Anhui 230001, China
  • Allist Investigative Site
    Beijing, Beijing Municipality 101119, China
  • Allist Investigative Site
    Chaoyang, Beijing Municipality 100021, China
  • Allist Investigative Site
    Chongqing, Chongqing Municipality 400030, China
  • Allist Investigative Site
    Harbin, Heilongjiang 150081, China
  • Allist Investigative Site
    Zhengzhou, Henan 450003, China
  • Allist Investigative Site
    Zhengzhou, Henan 450052, China
  • Allist Investigative Site
    Wuhan, Hubei 430022, China
  • Allist Investigative Site
    Xuzhou, Jiangsu 221000, China
  • Allist Investigative Site
    Nanchang, Jianxi 330008, China
  • Allist Investigative Site
    Changchun, Jilin 130012, China
  • Allist Investigative Site
    Jinan, Shandong 250021, China
  • Allist Investigative Site
    Jinan, Shandong 250117, China
  • Allist Investigative Site
    Taiyuan, Shanxi 030013, China
  • ArriVent Investigative Site
    Lyon, 69373, France
  • Arrivent Investigative Site
    Toulouse, 31059, France
  • Arrivent Investigative Site
    Villejuif, 94800, France
  • ArriVent Investigative Site
    Medolla, 47014, Italy
  • ArriVent Investigative Site
    Chiba, Chiba 260-0013, Japan
  • Arrivent Investigative Site
    Ōsaka-sayama, Osaka 589-8511, Japan
  • Arrivent Investigative Site
    Chūō, Tokyo 104-0045, Japan
  • Arrivent Investigative Site
    Koto-Ku, Tokyo 135-8550, Japan
  • Arrivent Investigative Site
    Amsterdam, North Holland 1066 CX, Netherlands
  • Arrivent Investigative Site
    Gwangju, 61469, South Korea
  • Arrivent Investigative Site
    Seoul, 2447, South Korea
  • ArriVent Investigative Site
    Barcelona, 08035, Spain
  • ArriVent Investigative Site
    Madrid, 28033, Spain
  • ArriVent Investigative Site
    Madrid, 28050, Spain
  • ArriVent Investigative Site
    Valencia, 46026, Spain
  • ArriVent Investigative Site
    London, NW12PG, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Jun 2025, 35 months.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 35 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2022
First posted
May 6, 2022
StartActual
Jun 30, 2022
Primary completionActual
Jun 3, 2025
CompletionEst.
Dec 31, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05364073
Lead sponsor
ArriVent BioPharma, Inc.
Responsible party
Sponsor
First posted
May 6, 2022
Start date
Jun 30, 2022
Primary completion
Jun 3, 2025
Completion
Dec 31, 2026 (estimated)
Last update
Nov 12, 2026

Study contacts

Jamuna Thimmarayappa
study director · ArriVent BioPharma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflutinib

Start the discussion